,0,1,2,3,4,5,6
0,,,Accession ID: NGSO-221209001,,,,Page 40 of 76
1,,,"Patient Name: LAN ZHENG,MEI-CHAN",,,,
2,,,Diagnosis: gastric cancer,,,,
3,YOURLAB,,,,,,
4,,,Trial Title,,,Trial,
5,Gene/Variant,,Trial ID,,Treatments,,Location / Contact
6,,,Colorectal Cancer,,,,
7,,,NCTO2675946,,,,
8,TP53,,"A Phase la/Ib, Open Label, Dose-",,miptenalimab,Phasel,"United States: CT, NY,"
9,p.R248Q,,escalation Study of the Combination of,,BI 907828,,
10,Tier 2C,,,,ezabenlimab,,
11,Pathogenic,,Combination of BI 9O7828 With BI,,,,clintriage.rdg@boehri
12,,,754091(Ezabenlimab) Followed by,,,,nger-ingelheim.com;
13,,,Advanced Solid Tumors,,,"Expansion Cohorts,in Patients With",
14,,,NCT03964233,,,,
15,TP53,,A Phase 2 Single-Arm Study of M662O,,irinotecan,,"United States: CA, FL,"
16,p.R248Q,,in Combination With Irinotecan in,,berzosertib,,
17,g.7674220C>T,,Patients With Progressive TP53 Mutant,,,,"OK,TN,UT"
18,Tier 2C,,Gastric and Gastro-Esophageal,,,,See clinicaltrials.gov
19,Pathogenic,,Junction Cancer,,,,NCT03641313
20,,,NCT03641313,,,,
21,Individual Variant Interpretations,,,,,,
22,,Biomarker TMB-low,,Interpretation,,,
23,Classification Tier 2C,,, No information available,,,
24,,Assessment Uncertain Significance,,,,,
25,,Biomarker MS-stable,,Interpretation,,,
26,Classification Tier 2C,,,No information available,,,
27,,Assessment Uncertain Significance,,,,,
28,,Gene CDKN2A,,Interpretation,,,
29,,Exon 2,,"The CDKN2A gene encodes multiple proteins, including the tumor",,,
30,,Nucleotide NM_000077.5:,,"suppressor pl6INK4a (also known as Mtsl), which plays a vital role in cell",,,
31,,,g.2197112G>A,cycle Gl checkpoint regulation and is an inhibitor of Cdk4 activity.,,,
32,,c.247C>T,,"CDKN2A also encodes pl4ARF, which regulates p53 by interacting with",,,
33,,Amino Acid p.H83Y,,"Mdm2 [278,232,279].Because the CDKN2A and CDKN2B gene products",,,
34,,Function loss,,"encode proteins that act as tumor suppressors, deletion or loss of activity",,,
35,Allelic Fraction 9.22% (of 206 reads),,,may result in deregulation of the pl6INK4a/Cdk4/Cyclin/Rb and/or the,,,
36,Classification Tier 2C,,,"Mdm2/p53 pathways, and altered regulation of the cell cycle [72, 279].",,,
37,,Assessment Pathogenic,,,,,
38,,Gene KRAS,,Interpretation,,,
39,,Exon 2,,"KRAS is an oncogene that encodes K-Ras, a member of the Ras family of",,,
40,,Nucleotide NM_004985.5:,,membrane proteins that bind GDP/GTP and possess GTPase activity,,,
41,,,g.25245350C>G,"Activation of Ras signaling causes cell growth, differentiation, and survival",,,
42,,c.35G>C,,,,,
43,,Amino Acid p.Gl2A,,,,,
44,,Function gain,,"human malignancies, with high incidences in pancreatic, colorectal, and",,,
45,Allelic Fraction 39.0% (of 160 reads),,,"Iung cancers [65, 84, 64].",,,
46,Classification Tier 2c,,,,,,
47,,Assessment Pathogenic,,,,,
